News
Extravascular ICD surpasses goals in pivotal trial
- Author:
- Mitchel L. Zoler, PhD
A novel “extravascular” ICD that avoids some limitations of prior ICD types surpassed its prespecified efficacy and safety goals in a pivotal...
News
MR and PET perform similarly for assessing CAD
- Author:
- Mitchel L. Zoler, PhD
Head-to-head comparison of rubidium PET and cardiac MR showed comparable performance for identifying coronary obstructions.
News
Albuminuria linked to higher CVD risk in diabetes
- Author:
- Mitchel L. Zoler, PhD
An analysis of more than 74,000 Danish people with type 2 diabetes showed an elevated CVD event rate in those with albuminuria.
News
Dapagliflozin’s HFpEF benefit recasts heart failure treatment: DELIVER
- Author:
- Mitchel L. Zoler, PhD
Results from DELIVER made dapagliflozin the third SGLT2 inhibitor to benefit patients with HFpEF, cementing a new, ejection fraction–agnostic...
Video
DAPA-HF: Dapagliflozin’s HFrEF efficacy confirmed in nondiabetics
- Author:
- Mitchel L. Zoler, PhD
PHILADELPHIA – Further analyses from the DAPA-HF trial showed dapagliflozin cut death and heart failure events...
Video
Flu vaccine cuts infection severity in kids and adults
- Author:
- Mitchel L. Zoler, PhD
Recent U.S. data compiled by the CDC documented that children and adults who received influenza vaccines had fewer severe infections.
Video
Oral beta-lactams provide noninferior postdischarge pyelonephritis treatment
- Author:
- Mitchel L. Zoler, PhD
WASHINGTON – Beta-lactams were noninferior to fluoroquinolones or trimethoprim-...
Video
DAPA-HF results transform dapagliflozin from antidiabetic to heart failure drug
- Author:
- Mitchel L. Zoler, PhD
PARIS – Proof that dapagliflozin significantly helped heart failure patients without diabetes recategorizes the...
Video
Overreliance on DAS scores undermines rheumatoid arthritis management
- Author:
- Mitchel L. Zoler, PhD
MADRID – A rheumatoid arthritis patient says “DAS blindness” now pervades rheumatoid arthritis management and degrades care.
Video
Obeticholic acid reversed NASH liver fibrosis in phase 3 trial
- Author:
- Mitchel L. Zoler, PhD
VIENNA – Phase 3 trial results showed obeticholic acid, already FDA approved, is the first drug to reverse liver fibrosis in NASH patients.
Video
New SLE classification criteria reset disease definition
- Author:
- Mitchel L. Zoler, PhD
A weighted-point system lets new SLE criteria classify patients solely by immunology and nephritis or by new...
Video
VIDEO: Hepatitis C eradication cuts nonliver cancer rate
- Author:
- Mitchel L. Zoler, PhD
WASHINGTON - U.S. data from thousands of treated hepatitis C patients implicates the virus as carcinogenic and a factor in a wide range of...
Video
VIDEO: Pelvic radiation surpasses brachytherapy/chemo for early endometrial cancer
- Author:
- Mitchel L. Zoler, PhD
Pelvic radiation produced similar recurrence-free survival as vaginal brachytherapy plus chemo but with less toxicity and fewer local recurrences...
Video
VIDEO: Dabigatran effective for myocardial injury after noncardiac surgery
- Author:
- Mitchel L. Zoler, PhD
ORLANDO – There’s now treatment for a condition that’s been rarely looked at until now.